41L Stock Overview
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Laboratorios Farmaceuticos Rovi, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €61.35 |
| 52 Week High | €91.30 |
| 52 Week Low | €57.50 |
| Beta | 0.49 |
| 1 Month Change | -1.21% |
| 3 Month Change | -17.87% |
| 1 Year Change | 6.70% |
| 3 Year Change | -12.61% |
| 5 Year Change | 163.30% |
| Change since IPO | 1,297.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 41L | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.1% | -2.5% | -1.4% |
| 1Y | 6.7% | -13.7% | 8.0% |
Return vs Industry: 41L exceeded the German Pharmaceuticals industry which returned -14.4% over the past year.
Return vs Market: 41L underperformed the German Market which returned 8.1% over the past year.
Price Volatility
| 41L volatility | |
|---|---|
| 41L Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 41L has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 41L's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,137 | Juan Lopez-Belmonte Encina | www.rovi.es |
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi.
Laboratorios Farmaceuticos Rovi, S.A. Fundamentals Summary
| 41L fundamental statistics | |
|---|---|
| Market cap | €3.17b |
| Earnings (TTM) | €165.00m |
| Revenue (TTM) | €799.25m |
19.2x
P/E Ratio4.0x
P/S RatioIs 41L overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 41L income statement (TTM) | |
|---|---|
| Revenue | €799.25m |
| Cost of Revenue | €310.33m |
| Gross Profit | €488.92m |
| Other Expenses | €323.92m |
| Earnings | €165.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.23 |
| Gross Margin | 61.17% |
| Net Profit Margin | 20.64% |
| Debt/Equity Ratio | 20.1% |
How did 41L perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield39%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 15:41 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Laboratorios Farmaceuticos Rovi, S.A. is covered by 18 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Álvaro Arístegui Echevarría | Ahorro Corporación |
| Guilherme Sampaio | Banco BPI, S.A. |
| Javier Esteban Lario | Banco de Sabadell. S.A. |